B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

KMT2A

MOLECULAR TARGET

lysine methyltransferase 2A

UniProt: Q03164NCBI Gene: 42976 compounds

KMT2A (lysine methyltransferase 2A) is targeted by 6 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting KMT2A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1s adenosylhomocysteine1.102
2Tannins Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS).0.691
3Aurintricarboxylic Acid0.691
4Nitroblue Tetrazolium Colorless to yellow dye that is reducible to blue or black formazan crystals by certain cells; formerly used to distinguish between nonbacterial and bacterial diseases,0.691
5scutellarein0.691
6Suramin0.691

About KMT2A as a Drug Target

KMT2A (lysine methyltransferase 2A) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 6 compounds with documented KMT2A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

KMT2A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.